Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the Phase 2 trial of Lucid-MS, Quantum's lead drug candidate for multiple sclerosis (MS). The agreement moves the innovative treatment from planning into execution, according to the company.
Most MS drugs work by quieting the immune system. Lucid-MS is designed around a novel neuroprotective approach that targets demyelination—the damage to the protective sheath around nerve fibers—rather than solely modulating the immune system. This could represent a significant shift in MS treatment, as current therapies primarily focus on reducing immune attacks but do not directly repair or protect myelin. By targeting demyelination, Lucid-MS aims to preserve nerve function and potentially slow disease progression.
Thermo Fisher's clinical research business is a leading global contract research organization with expertise in central nervous system and MS studies. Their involvement lends credibility and operational scale to the Phase 2 trial, which is a critical step in determining whether Lucid-MS is safe and effective in patients. The study start-up agreement signals that the trial is moving forward, with Thermo Fisher handling implementation.
The partnership highlights a differentiated approach in the competitive MS market. If successful, Lucid-MS could offer an alternative or complement to existing immunomodulatory therapies. For patients, this could mean new options that address the underlying neurodegeneration associated with MS. For investors, it marks a key milestone for Quantum BioPharma, validating its proprietary platform and advancing its pipeline.
Quantum BioPharma's news is being disseminated through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
For more information on Quantum BioPharma, visit their client page at https://ibn.ai/clients/quantum-biopharma-ltd/. To read the full press release, visit https://www.investorwire.com/?post_type=newsarticles&p=40240. Details on the Study Start-Up Agreement can be found at https://ibn.fm/njHL0. InvestorWire's services are described at https://www.investorwire.com/, and its parent company IBN at https://www.investorbrandnetwork.com/. Full terms of use and disclaimers are available at https://www.investorwire.com/Disclaimer.
